| Drug Name |
Icatibant |
| Drug ID |
BADD_D02452 |
| Description |
Icatibant (Firazyr) is a synthetic peptidomimetic drug consisting of ten amino acids, and acts as an effective and specific antagonist of bradykinin B2 receptors. It has been approved in the EU for use in hereditary angioedema, and is under investigation for a number of other conditions in which bradykinin is thought to play a significant role. Icatibant currently has orphan drug status in the United States and FDA approved on August 25, 2011. |
| Indications and Usage |
Approved for use in acute attacks of hereditary angioedema (HAE). Investigated for use/treatment in angioedema, liver disease, and burns and burn infections. |
| Marketing Status |
approved; investigational |
| ATC Code |
B06AC02 |
| DrugBank ID |
DB06196
|
| KEGG ID |
D04492
|
| MeSH ID |
C065679
|
| PubChem ID |
6918173
|
| TTD Drug ID |
D04ZBT
|
| NDC Product Code |
63323-574; 71225-114; 69097-664; 70709-013; 0093-3066; 24201-207 |
| UNII |
7PG89G35Q7
|
| Synonyms |
icatibant | D-Arg(Hyp(3)-Thi(5)-D-Tic(7)-Oic(8))BK | icatibant acetate | HOE-140 | HOE140 | Firazyr | Hoechst-140 | HOE 140 | Hoechst 140 | JE 049 | JE-049 | WIN 65365 | D-Arg(Hyp(3)-Thi(5)-L-Tic(7)-Oic(8))BK | WIN-65365 |
